Rocket Doctor AI Inc. Expands U.S. Team and Leadership to Accelerate Growth
Rocket Doctor AI Inc. (OTC: RDK) announced a series of organizational changes on 5 November 2025 aimed at strengthening its U.S. presence and driving future growth. The company’s leadership team has been expanded with new appointments in key operational roles, including a chief operating officer and regional directors for the east and west coasts. These appointments are intended to facilitate the company’s strategy of expanding access to care across the United States.
The company’s board issued a formal statement highlighting the expected impact of the new appointments. The additions are described as “critical to scaling operations, improving customer experience, and supporting the rollout of Rocket Doctor’s AI‑driven clinical solutions.” The board also noted that the expanded team would oversee the development of new market‑specific services and manage regulatory compliance as the company expands its footprint.
In the same day’s announcement, Rocket Doctor AI Inc. released a press release on the OTC Bulletin Board confirming the leadership changes. The release emphasized the company’s commitment to leveraging artificial intelligence to streamline clinical workflows and enhance diagnostic accuracy for patients nationwide.
While the company has not disclosed financial details in the leadership announcement, its latest market data shows a closing price of USD 0.56 on 5 November 2025, a 52‑week high of USD 0.73 reached on 11 November 2024, and a 52‑week low of USD 0.078 reached on 17 February 2025. Rocket Doctor AI Inc. has a market capitalization of approximately USD 73.35 million and a price‑earnings ratio of –3.938, indicating that the company is currently operating at a loss.
The expansion of Rocket Doctor’s U.S. team is positioned to support the company’s broader strategic objective of increasing market penetration and accelerating revenue growth, in line with the company’s stated focus on expanding access to care coast to coast.
